ITeos Therapeutics Inc. is a clinical-stage biopharmaceutical company that develops novel therapies for cancer treatment. The company's proprietary immuno-oncology platform is designed to stimulate the immune system to attack cancer cells. ITeos' lead product candidate, EOS-448, is a monoclonal antibody that targets the T cell immunoglobulin and mucin domain-containing protein 3 (TIM-3), a checkpoint protein that can suppress T cell activation and effector function. ITOS-448 is currently in phase 1/2a clinical trials for the treatment of solid tumors.
ITeos has a pipeline of other product candidates in various stages of development, including ITOS-6820, a small molecule inhibitor of the lysine-specific demethylase 1 (LSD1) enzyme, which is being developed for the treatment of small cell lung cancer, and ITOS-1480, an inhibitor of the immunosuppressive enzyme arginase 1, which is being developed for the treatment of solid tumors.
The company was founded in 2011 and is headquartered in Cambridge, Massachusetts.
ITeos Therapeutics Inc. is a clinical-stage biopharmaceutical company that develops novel therapies for cancer treatment. The company's proprietary immuno-oncology platform is designed to stimulate the immune system to attack cancer cells. ITeos' lead product candidate, EOS-448, is a monoclonal antibody that targets the T cell immunoglobulin and mucin domain-containing protein 3 (TIM-3), a checkpoint protein that can suppress T cell activation and effector function. ITOS-448 is currently in phase 1/2a clinical trials for the treatment of solid tumors.